- PA5-17805 - Invitrogen Antibodies BCL2L1 antibody

Submitted references Retinal Protection from LED-Backlit Screen Lights by Short Wavelength Absorption Filters.

Sanchez-Ramos C, Bonnin-Arias C, Blázquez-Sánchez V, Aguirre-Vilacoro V, Cobo T, García-Suarez O, Perez-Carrasco MJ, Alvarez-Peregrina C, Vega JA
Cells 2021 Nov 19;10(11)

Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells.

Konac E, Varol N, Kiliccioglu I, Bilen CY
Oncology letters 2015 Jul;10(1):560-564

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of Bcl-xL was achieved by transfecting A549 with Bcl-xL specific siRNAs (Silencer® select Product # S1921, S1920). Western blot analysis (Fig. a) was performed using Whole cell extracts from the Bcl-xL untransfected cells (lane 1), non-targeting scrambled siRNA transfected cells (lane 2) and knockdown cells (lane 3). The blot was probed with Bcl-xL Polyclonal Antibody (Product # PA5-17805, 1:1000 dilution) and Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to Bcl-xL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot was performed using Anti-Bcl-xL Polyclonal Antibody(Product # PA5-17805) and a 25kDa band corresponding to Bcl-xL was observed across cell lines tested. Whole cell extracts (30 µg lysate) of A-431 (Lane 1), NIH:OVCAR-3 (Lane 2), Hep G2 (Lane 3), NIH/3T3 (Lane 4), PC-12 (Lane 5), A549 (Lane 6) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a Nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 Dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036,1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of Bcl-xL was performed using 70% confluent log phase A549 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with Bcl-xL Polyclonal Antibody (Product # PA5-17805) at 5 µg in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034), (1:2000 dilution), for 45 minutes at room temperature (Panel a: Green). Nuclei (Panel b:Blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300 dilution). Panel d represents the merged image showing Cytoplasm localization. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60x magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

PA5-17805

Antibody data